I hereby certify that this correspondence and deposited with the U.S. Postal Service, as Express Mail, Airbill No. ET575269979US, in an envelope addressed to: Box RCE, Commissioner for Patents, Washington, DC 20231, on the date shown below.

OCT 2 9 2001

ORIGINAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of: James M. Musser and V. Kapur

Atty. Docket: P00965US0

Application No.: 08/160.965

Group Art Unit: 1645

Filed: December 2, 1993

Examiner: J. Hines

For: VACCINES CONTAINING CYSTEINE PROTEASE AND METHODS TO PROTECT RECEIVED JAN 1 0 2002

AGAINST GROUP A STREPTOCOCCI

TECH CENTER 1600/2900

AMENDMENT UNDER 37 CFR 1.116

Box RCE

Commissioner for Patents Washington, DC 20231

Dear Sir:

In response to the Office Action dated May 30, 2001, and the Advisory Action mailed October 25, 2001, please amend the above-identified U.S. Patent application as follows:

In the Claims

4-6.

Please cancel claim 3. Please substitute the below amended claims for claims 1 and

1. (Amended four times) A vaccine comprising:

a physiologically acceptable non-toxic vehicle containing a purified nonproteolytic cysteine protease, which confers immunity to a mammal against Group A streptococcal infection, wherein said cysteine protease comprises at least one amino acid substitution and said amino acid substitution occurs at the amino acid position selected from the group consisting of Lys145. Gln185, Cys192, His340, Asn356 and Trp357.

01/09/2002 GTEFFERA 00000061 062375 08160965

03 FC:103 04 FC:102 05 FC:104

756.00 CH

25088171.1